SelectQuote (NYSE: SLQT) experienced a dramatic selloff on Tuesday, with shares closing down 30.4% at $0.5402 after the company released a fiscal 2027 revenue outlook that fell significantly short of analyst expectations. The disappointing guidance has exacerbated the company's ongoing struggle to regain compliance with the New York Stock Exchange's $1 minimum share price requirement.
The Overland Park, Kansas-based insurance distribution and healthcare services company reported fourth-quarter revenue of $321.7 million, a 7% decline from the prior-year period and roughly $31.7 million below the consensus estimate of $353.4 million. The company also swung to a net loss of $16.8 million, compared to a net profit of $12.9 million in the same quarter last year.
More concerning for investors was the company's fiscal 2027 revenue guidance of $1.35 billion to $1.45 billion. The midpoint of $1.40 billion sits 19.5% below the consensus estimate of $1.74 billion and represents a year-over-year decline of approximately 9% to 16% from fiscal 2026 levels. This projection signals a deliberate pullback in growth initiatives as management prioritizes cash generation over top-line expansion.
CEO Tim Danker emphasized the company's new strategic focus, stating that full-year 2027 operating cash flow is expected to approximately double to over $60 million. The company also forecasts free cash flow of roughly $50 million and annual technology-enabled savings exceeding $30 million. This pivot toward profitability and cash flow comes as the company faces significant balance sheet challenges.
SelectQuote disclosed approximately $370.2 million in current and long-term debt, along with preferred stock carrying a $423.2 million liquidation preference. The company's operating cash flow for fiscal 2026 improved to $31.9 million, up $43.6 million from the prior year, but the substantial debt load continues to weigh on the stock.
The NYSE notified SelectQuote of a listing deficiency in March, as the stock's closing price remained below the $1 threshold. From Tuesday's close of $0.5402, the shares would need to rally 85.1% to reach the $1 minimum. The company has been granted a cure period in accordance with exchange requirements and an approved compliance plan.
Segment performance was mixed during the quarter. Revenue from the senior segment decreased 12%, with approved Medicare Advantage policies down 15%. SelectRx membership grew 1% with a 3.5% increase in daily prescriptions, but Healthcare Services revenue registered a 10% decline. Adjusted EBITDA for the fourth quarter climbed to $11.9 million from $2.7 million in the prior year, with the Life segment's adjusted EBITDA up 41% despite flat revenue.
The market's reaction reflects deep skepticism about the company's ability to execute its turnaround strategy. The mean analyst price target of $3.06 implies a potential gain of 466.5% from current levels, but this wide gap highlights outdated targets and limited coverage. With only a handful of analysts following the stock, the market is pricing in significant execution and financing risks.
Investors will now focus on whether SelectRx prescription growth can translate into the anticipated cash flow improvements. The $1 share price level remains the critical benchmark that could validate or further undermine the company's operating strategy. If the company fails to show progress on its cash flow initiatives or if Medicare demand weakens further, the stock could face additional pressure.